Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 263

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 8
Chunk 263
---
 )

    (28,566
    )

    CASH FLOWS FROM INVESTING ACTIVITIES:

    Proceeds from the sale of marketable equity securities

    18

    196

    Purchases of marketable debt securities

    (8,761
    )

    (16,403
    )

    Maturities of marketable debt securities

    7,000

    63,330

    Purchase of equipment

    (565
    )

    (674
    )

    Net cash (used in) provided by investing activities

    (2,308
    )

    46,449

    CASH FLOWS FROM FINANCING ACTIVITIES:

    Proceeds from employee options exercised

    229

    88

    Common shares received and retired for employee taxes paid

    (23
    )

    (37
    )

    Proceeds from sale of common shares under ATM, net of offering costs

    68

    6,426

    Proceeds from sale of common shares under registered direct financing, net of offering costs

    13,889

    —

    Proceeds from sale of common shares with warrants under registered direct financing, net of offering costs

    21,919

    —

    Payment of financed insurance premium

    (171
    )

    —

    Repayment of finance lease liabilities

    (54
    )

    (54
    )

    Net cash provided by financing activities

    35,857

    6,423

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

    (95
    )

    (250
    )

    NET INCREASE IN CASH, CASH EQUIVALENTS AND    RESTRICTED CASH

    10,362

    24,056

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH:

    At beginning of the period

    35,992

    11,936

    At end of the period
     
    $
    46,354

    $
    35,992

    SUPPLEMENTAL DISCLOSURES:

    Cash paid for interest
     
    $
    9

    $
    10

    SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND    INVESTING ACTIVITIES:

    Financing costs in accounts payable and accrued liabilities